Identity
- Security key
- 23354
- Ticker
- VIR
- Type
- CS — Common Stock
- Exchange
- Nasdaq(XNAS)
- Venue group
- NASDAQ
- Operating MIC
- XNAS
- Market
- stocks
- Locale
- us
- Currency
- USD
- Listed
- 2019-10-11
- Round lot
- 100
- Active
- Yes
- Last seen in a load
- 2026-08-14 20:49
- Vendor updated
- 2026-08-13 06:09
- Ticker root / suffix
- VIR
Detail
Enriched 2026-08-14 20:47
- Market cap
- $1,516,174,983.68
- Shares outstanding (class)
- 169,215,958
- Shares outstanding (weighted)
- 169,215,958
- SIC
- 2836 BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
- Employees
- 367
- Location
- SAN FRANCISCO, CA
- Homepage
- https://www.vir.bio
- Description
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.